Hornby 2012

Methods	Method: RCT, cross‐over assignment Method of randomisation: not described Blinding of outcome assessors: yes Adverse events: not described Deaths: not described Drop outs: not described ITT: not described
Participants	Country: USA 30 people with chronic stroke Ambulatory at study onset: not clearly described, probably yes Inclusion criteria: unilateral supratentorial stroke; MMSE > 22; > 6 months stroke duration; < 0.9 m/s gait speed overground. Exclusion criteria: lower extremity contracture; osteoporosis; cardiovascular/metabolic/respiratory instability; previous central/peripheral nerve injury; concurrent medications interacting with selective serotonin reuptake inhibitors (SSRIs)
Interventions	2 arms: CTL group will receive placebo drug alone or with BWSTT for 4 weeks EXP group will receive SSRIs alone or with BWSTT for 4 weeks
Outcomes	Outcomes will be assessed at baseline and at the end of the intervention phase at 4 weeks: Primary outcomes: peak treadmill speed Secondary outcomes: overground walking speed Other outcomes: gait kinematics, EMG activity
Notes